These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34572463)

  • 21. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
    Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
    J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of the immune checkpoint receptor TIGIT in seminoma.
    Hinsch A; Blessin NC; Simon R; Kluth M; Fischer K; Hube-Magg C; Li W; Makrypidi-Fraune G; Wellge B; Mandelkow T; Debatin NF; Höflmayer D; Lennartz M; Sauter G; Izbicki JR; Minner S; Büscheck F; Uhlig R; Dum D; Krech T; Luebke AM; Wittmer C; Jacobsen F; Burandt E; Steurer S; Wilczak W
    Oncol Lett; 2019 Aug; 18(2):1497-1502. PubMed ID: 31423216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity.
    Zhong Z; Zhang M; Ning Y; Mao G; Li X; Deng Q; Chen X; Zuo D; Zhao X; Xie E; Wang H; Guo L; Li B; Xiao K; He X
    Sci Rep; 2022 Oct; 12(1):18011. PubMed ID: 36289396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.
    Chu X; Tian W; Wang Z; Zhang J; Zhou R
    Mol Cancer; 2023 Jun; 22(1):93. PubMed ID: 37291608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies.
    Jin S; Zhang Y; Zhou F; Chen X; Sheng J; Zhang J
    Front Oncol; 2022; 12():1091782. PubMed ID: 36605439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update in TIGIT Immune-Checkpoint Role in Cancer.
    Annese T; Tamma R; Ribatti D
    Front Oncol; 2022; 12():871085. PubMed ID: 35656508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
    Kreidieh FY; Tawbi HA
    Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.
    Chiang EY; Mellman I
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes.
    Meng F; Li L; Lu F; Yue J; Liu Z; Zhang W; Fu R
    Front Oncol; 2020; 10():1595. PubMed ID: 32903786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The immune checkpoint TIGIT is upregulated on T cells during bacterial infection and is a potential target for immunotherapy.
    McCulloch TR; Rossi GR; Miranda-Hernandez S; Valencia-Hernandez AM; Alim L; Belle CJ; Krause A; Zacchi LF; Lam PY; Nakamura K; Kupz A; Wells TJ; Souza-Fonseca-Guimaraes F
    Immunol Cell Biol; 2024 Jun; ():. PubMed ID: 38873699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation.
    Han JH; Cai M; Grein J; Perera S; Wang H; Bigler M; Ueda R; Rosahl TW; Pinheiro E; LaFace D; Seghezzi W; Williams SMG
    Front Immunol; 2020; 11():573405. PubMed ID: 33117369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.
    Chen X; Song X; Li K; Zhang T
    Front Immunol; 2019; 10():292. PubMed ID: 30863404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TIGIT in cancer immunotherapy.
    Chauvin JM; Zarour HM
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
    Yadav R; Hakobyan N; Wang JC
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.
    Chen X; Wu W; Wei W; Zou L
    Front Pharmacol; 2022; 13():869488. PubMed ID: 35559250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
    Kok VC
    Front Oncol; 2020; 10():268. PubMed ID: 32185135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8
    Shaw G; Cavalcante L; Giles FJ; Taylor A
    J Hematol Oncol; 2022 Sep; 15(1):134. PubMed ID: 36104795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients.
    Pawłowska A; Skiba W; Suszczyk D; Kuryło W; Jakubowicz-Gil J; Paduch R; Wertel I
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.